

# ARVO 2020

**CONTROL ID:** 3348047

**SUBMISSION ROLE:** Abstract Submission

## **AUTHORS**

**AUTHORS (LAST NAME, FIRST NAME):** Shorter, Ellen<sup>1</sup>; Perera, Chamila<sup>3</sup>; Migneco, Mary<sup>3</sup>; Whiteside, Meredith<sup>4</sup>; Harthan, Jennifer<sup>2</sup>; Hartwick, Andrew<sup>5</sup>; Johnson, Spencer<sup>6</sup>; Morettin, Christina<sup>2</sup>; Huecker, Julia<sup>3</sup>; Than, Tammy<sup>7</sup>; Gordon, Mae<sup>3</sup>

**INSTITUTIONS (ALL):** 1. Ophthalmology and Vision Sciences, University of Illinois at Chicago, Chicago, IL, United States.

2. Illinois College of Optometry, IL, United States.

3. Washington University in Saint Louis, MO, United States.

4. UC Berkeley School of Optometry, CA, United States.

5. Ohio State University, OH, United States.

6. Northeastern State University, OK, United States.

7. Carl Vinson VA Medical Center, GA, United States.

**Commercial Relationships Disclosure (Abstract):** Ellen Shorter: Commercial Relationship(s); Johnson and Johnson: Code F (Financial Support) | Chamila Perera: Commercial Relationship: Code N (No Commercial Relationship) | Mary Migneco: Commercial Relationship: Code N (No Commercial Relationship) | Meredith Whiteside: Commercial Relationship: Code N (No Commercial Relationship) | Jennifer Harthan: Commercial Relationship(s); Allergan: Code R (Recipient); Essilor: Code R (Recipient); Kala: Code F (Financial Support); Tangible Science: Code F (Financial Support); Shire: Code F (Financial Support); Synergeyes: Code R (Recipient); Contamac: Code R (Recipient); Essilor: Code C (Consultant); Metro: Code C (Consultant); Metro: Code R (Recipient); Takeda: Code R (Recipient); Metro: Code F (Financial Support); Contamac: Code F (Financial Support) | Andrew Hartwick: Commercial Relationship: Code N (No Commercial Relationship) | Spencer Johnson: Commercial Relationship: Code N (No Commercial Relationship) | Christina Morettin: Commercial Relationship: Code N (No Commercial Relationship) | Julia Huecker: Commercial Relationship: Code N (No Commercial Relationship) | Tammy Than: Commercial Relationship: Code N (No Commercial Relationship) | Mae Gordon: Commercial Relationship(s); DiaSorin: Code F (Financial Support)

**Study Group:** (none)

## **ABSTRACT**

**TITLE:** Improving accuracy of adenoviral conjunctivitis diagnosis

### **ABSTRACT BODY:**

**Purpose:** To improve diagnostic accuracy of adenoviral conjunctivitis (Ad-Cs) with a multivariate model using presenting signs and symptoms.

**Methods:** Patients with acute red eye(s) and presumed Ad-Cs were enrolled at 9 clinics for eligibility in the Reducing Adenoviral Patient Infected Days (RAPID) study. Inclusion criteria were  $\geq 18$  years old with

symptoms  $\leq$  4 days. The initial visit included conjunctival swab sample for qPCR Ad-Cs analysis, AdenoPlus point-of-care immunoassay (POCT) (QuickVue Test by Quidel, San Diego, CA) and the following clinical signs and symptoms (Table 1).

Variables were first screened based on the random forest variable importance measures. Penalized logistic regression was used to select a subset of variables that differentiated between Ad-Cs positive and negative patients. "Area under the curve" (AUC) was used to compare the prediction performance of different models.

**Results:** Of 212 participants, 185 had conjunctival swab samples, POCT and screening examination, of which, 30 tested positive for Ad-Cs by qPCR and 155 tested negative. The POCT had positive and negative predictive values of 50% and 98.5%, respectively. AUC for differentiating between qPCR positive and negative patients was 0.84 for slit lamp and physical exam findings, 0.69 for exposure factors, 0.76 for systemic symptoms, 0.82 for patient-symptoms and 0.87 for POCT. When the POCT was added to slit lamp and physical exam findings, the AUC increased from 0.84 to 0.95.

**Conclusions:** Although clinical findings such as lid edema, serous discharge, redness, conjunctival follicles and presence of pre-auricular nodes can provide reasonable accuracy in the diagnosis of Ad-Cs, when available, POCT can further improve diagnostic accuracy.

## **DETAILS**

**PRESENTATION TYPE:** #1 Poster, #2 Paper

**CURRENT REVIEWING CODE:** 1470 Corneal immunology and infections - IM

**CURRENT SECTION:** Immunology/Microbiology

**Clinical Trial Registration (Abstract):** Yes - <http://www.clinicaltrials.gov>

**Other Registry Site (Abstract):** (none)

**Registration Number (Abstract):** NCT02472223

**Date Trial was Registered (MM/DD/YYYY) (Abstract):** 06/15/2015

**Date Trial Began (MM/DD/YYYY) (Abstract):** 03/01/2015

**Grant Support (Abstract):** Yes

**Support Detail (Abstract):** National Eye Institute Center R34 Grant (EY023633-01A1), a National Eye Institute Center Core Grant (P30EY002687), R21 Grant (EY030524-01) and an unrestricted grant to the Department of Ophthalmology and Visual Sciences from Research to Prevent Blindness

## **TRAVEL GRANTS and AWARDS APPLICATIONS**

**AWARDS:**

## **AFFIRMATIONS**

**Affirmations:** Affirmation of compliance with ARVO's Statement for Use of Animals.

**Affirmations:** Affirmation to reveal essential structure, novel compound elements, or identify new gene compounds.

**Affirmations:** Affirmation of compliance with ARVO's Statement for Use of Human Subjects and/or Declaration of Helsinki.

**Affirmations:** Affirmation that submission of this abstract has been approved by the Principal Investigator.

**Affirmations:** Affirmation of copyright transfer from each author to ARVO, or certification of public domain abstract.

**Affirmations:** Affirmation of compliance with ARVO policy on registering clinical trials.

**Affirmations:** Affirmation to present same work as abstract submission.

**Affirmations:** Affirmation that abstract data/conclusions have not been published; not redundant with other submissions from same investigators.

**Affirmations:** Affirmation to pay Annual Meeting's full registration fee.